Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 11 de 11
Filtrar
1.
Am J Med Genet A ; 185(8): 2361-2373, 2021 08.
Artigo em Inglês | MEDLINE | ID: mdl-33960638

RESUMO

To use national mortality and state death certificate records to estimate disease specific mortality rates among pediatric and adult populations for 23 leukodystrophies (LDs) with pediatric forms. Additionally, to calculate yearly prevalence and caseload of the most severe LD cases that will eventually result in pediatric death (i.e., pediatric fatality cases). Death certificate records describing cause of death were collected from states based on 10 ICD-10 codes associated with the 23 LDs. Deaths in the U.S. with these codes were distributed into categories based on proportions identified in state death certificate data. Mortality rates, prevalence, and caseload were calculated from resulting expected numbers, population sizes, and average lifetimes. An estimated 1.513 per 1,000,000 0-17 year old's died of these LDs at average age 5.2 years and 0.194 for those ≥18 at an average age of 42.3 years. Prevalence of pediatric fatality cases of these LDs declined from 1999 through 2007 and then remained constant at 6.2 per million children per year through 2012. Epidemiological information, currently lacking for rare diseases, is useful to newborn screening programs, research funding agencies, and care centers for LD patients. Methods used here are generally useful for studying rare diseases.


Assuntos
Leucodistrofia Metacromática/mortalidade , Fatores Etários , Algoritmos , Causas de Morte , Análise de Dados , História do Século XX , História do Século XXI , Humanos , Leucodistrofia Metacromática/epidemiologia , Leucodistrofia Metacromática/etiologia , Leucodistrofia Metacromática/história , Mortalidade , Vigilância da População , Prevalência , Estados Unidos/epidemiologia
2.
Biol Blood Marrow Transplant ; 25(2): 328-334, 2019 02.
Artigo em Inglês | MEDLINE | ID: mdl-30292746

RESUMO

Allogeneic blood or marrow transplantation (BMT) is currently considered the standard of care for patients with specific inborn errors of metabolism (IEM). However, there is a paucity of studies describing long-term survival and cause-specific late mortality after BMT in these patients with individual types of IEM. We studied 273 patients who had survived ≥2 years after allogeneic BMT for IEM performed between 1974 and 2014. The most prevalent IEM in our cohort were X-linked adrenoleukodystrophy (ALD; 37.3%), Hurler syndrome (35.1%), and metachromatic leukodystrophy (MLD; 10.2%). Conditional on surviving ≥2 years after BMT, the overall survival for the entire cohort was 85.5 ± 2.4% at 10 years and 73.5 ± 3.7% at 20 years. The cohort had a 29-fold increased risk of late death compared with an age- and sex-matched cohort from the general US population (95% CI, 22- to 38-fold). The increased relative mortality was highest in the 2- to 5-year period after BMT (standardized mortality ratio [SMR], 207; 95% confidence interval [CI], 130 to 308) and declined with increasing time from BMT, but remained elevated for ≥21 years after BMT (SMR, 9; 95% CI, 4 to 18). Sequelae from the progression of primary disease were the most common causes of late mortality in this cohort (76%). The use of T cell-depleted grafts in patients with ALD and Hurler syndrome was a risk factor for late mortality. Younger age at BMT and use of busulfan and cyclosporine were protective in patients with Hurler syndrome. Our findings demonstrate relatively favorable overall survival in ≥2-year survivors of allogeneic BMT for IEM, although primary disease progression continues to be responsible for the majority of late deaths.


Assuntos
Adrenoleucodistrofia/mortalidade , Transplante de Medula Óssea , Transplante de Células-Tronco Hematopoéticas , Leucodistrofia Metacromática/mortalidade , Mucopolissacaridose I/mortalidade , Adolescente , Adrenoleucodistrofia/terapia , Adulto , Criança , Pré-Escolar , Intervalo Livre de Doença , Feminino , Seguimentos , Humanos , Lactente , Recém-Nascido , Leucodistrofia Metacromática/terapia , Masculino , Pessoa de Meia-Idade , Mucopolissacaridose I/terapia , Estudos Retrospectivos , Taxa de Sobrevida , Transplante Homólogo
3.
Blood Adv ; 2(1): 49-60, 2018 01 09.
Artigo em Inglês | MEDLINE | ID: mdl-29344584

RESUMO

Leukodystrophies (LD) are devastating inherited disorders leading to rapid neurological deterioration and premature death. Hematopoietic stem cell transplantation (HSCT) can halt disease progression for selected LD. Cord blood is a common donor source for transplantation of these patients because it is rapidly available and can be used without full HLA matching. However, precise recommendations allowing care providers to identify patients who benefit from HSCT are lacking. In this study, we define risk factors and describe the early and late outcomes of 169 patients with globoid cell leukodystrophy, X-linked adrenoleukodystrophy, and metachromatic leukodystrophy undergoing cord blood transplantation (CBT) at an European Society for Blood and Marrow Transplantation center or at Duke University Medical Center from 1996 to 2013. Factors associated with higher overall survival (OS) included presymptomatic status (77% vs 49%; P = .006), well-matched (≤1 HLA mismatch) CB units (71% vs 54%; P = .009), and performance status (PS) of >80 vs <60 or 60 to 80 (69% vs 32% and 55%, respectively; P = .003). For patients with PS≤60 (n = 20) or 60 to 80 (n = 24) pre-CBT, only 4 (9%) showed improvement. Of the survivors with PS >80 pre-CBT, 50% remained stable, 20% declined to 60 to 80, and 30% to <60. Overall, an encouraging OS was found for LD patients after CBT, especially for those who are presymptomatic before CBT and received adequately dosed grafts. Early identification and fast referral to a specialized center may lead to earlier treatment and, subsequently, to improved outcomes.


Assuntos
Adrenoleucodistrofia/terapia , Transplante de Células-Tronco de Sangue do Cordão Umbilical , Leucodistrofia de Células Globoides/terapia , Leucodistrofia Metacromática/terapia , Adrenoleucodistrofia/mortalidade , Criança , Pré-Escolar , Feminino , Humanos , Lactente , Leucodistrofia de Células Globoides/mortalidade , Leucodistrofia Metacromática/mortalidade , Masculino , Fatores de Risco , Análise de Sobrevida , Fatores de Tempo , Resultado do Tratamento
4.
Arq Neuropsiquiatr ; 74(12): 953-966, 2016 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-27991992

RESUMO

OBJECTIVE: To describe survival and neurological outcomes after HSCT for these disorders. METHODS: Seven CALD, 2 MLD and 2 MPS-IH patients underwent HSCT between 2007 and 2014. Neurological examinations, magnetic resonance imaging, molecular and biochemical studies were obtained at baseline and repeated when appropriated. RESULTS: Favorable outcomes were obtained with 4/5 related and 3/6 unrelated donors. Two patients died from procedure-related complications. Nine transplanted patients were alive after a median of 3.7 years: neurological stabilization was obtained in 5/6 CALD, 1/2 MLD, and one MPS-IH patient. Brain lesions of the MPS-IH patient were reduced four years after HSCT. CONCLUSION: Good outcomes were obtained when HSCT was performed before adulthood, early in the clinical course, and/or from a related donor.


Assuntos
Adrenoleucodistrofia/cirurgia , Transplante de Células-Tronco Hematopoéticas , Leucodistrofia Metacromática/cirurgia , Mucopolissacaridose I/cirurgia , Adolescente , Adrenoleucodistrofia/genética , Adrenoleucodistrofia/mortalidade , Adulto , Idade de Início , Encéfalo/diagnóstico por imagem , Encéfalo/patologia , Brasil/epidemiologia , Criança , Pré-Escolar , Feminino , Transplante de Células-Tronco Hematopoéticas/mortalidade , Humanos , Leucodistrofia Metacromática/genética , Leucodistrofia Metacromática/mortalidade , Imageamento por Ressonância Magnética , Masculino , Mucopolissacaridose I/genética , Mucopolissacaridose I/mortalidade , Linhagem , Estudos Retrospectivos , Doadores de Tecidos , Condicionamento Pré-Transplante/métodos , Resultado do Tratamento , Substância Branca/diagnóstico por imagem , Adulto Jovem
5.
Arq. neuropsiquiatr ; 74(12): 953-966, Dec. 2016. tab, graf
Artigo em Inglês | LILACS | ID: biblio-828003

RESUMO

ABSTRACT Hematopoietic stem cell transplantation (HSCT) is the only available treatment for the neurological involvement of disorders such as late-onset metachromatic leukodystrophy (MLD), mucopolysaccharidosis type I-Hurler (MPS-IH), and X-linked cerebral adrenoleukodystrophy (CALD). Objective To describe survival and neurological outcomes after HSCT for these disorders. Methods Seven CALD, 2 MLD and 2 MPS-IH patients underwent HSCT between 2007 and 2014. Neurological examinations, magnetic resonance imaging, molecular and biochemical studies were obtained at baseline and repeated when appropriated. Results Favorable outcomes were obtained with 4/5 related and 3/6 unrelated donors. Two patients died from procedure-related complications. Nine transplanted patients were alive after a median of 3.7 years: neurological stabilization was obtained in 5/6 CALD, 1/2 MLD, and one MPS-IH patient. Brain lesions of the MPS-IH patient were reduced four years after HSCT. Conclusion Good outcomes were obtained when HSCT was performed before adulthood, early in the clinical course, and/or from a related donor.


RESUMO O transplante de células tronco hematopoiéticas (TCTH) é o único tratamento disponível para o envolvimento neurológico de doenças como a leucodistrofia metacromática (MLD), a mucopolissacaridose tipo I-Hurler (MPS-IH) e a adrenoleucodistrofia (CALD). Objetivos Descrever a sobrevida e os desfechos neurológicos após o TCTH nessas doenças. Métodos Sete pacientes CALD, 2 MLD e 2 MPS-IH realizaram TCTH entre 2007 e 2014. Avaliações neurológicas, ressonância nuclear magnética e estudos bioquímicos e moleculares foram feitos no baseline e repetidos quando apropriado. Resultados Desfechos favoráveis foram obtidos em 4/5 TCTH de doadores relacionados e em 3/6 não relacionados. Dois pacientes faleceram de complicações do procedimento. Nove transplantados sobreviveram após uma mediana de 3,7 anos: estabilização neurológica foi obtida em 5/6 CALD, ½ MLD e em um caso MPS-IH. As lesões encefálicas de um caso MPS-IH reduziram-se quatro anos após o TCTH. Conclusão Bons desfechos foram obtidos quando o TCTH foi feito antes da vida adulta, cedo no curso clínico e/ou a partir de um doador relacionado.


Assuntos
Humanos , Masculino , Feminino , Pré-Escolar , Criança , Adolescente , Adulto , Adulto Jovem , Mucopolissacaridose I/cirurgia , Transplante de Células-Tronco Hematopoéticas/mortalidade , Adrenoleucodistrofia/cirurgia , Leucodistrofia Metacromática/cirurgia , Linhagem , Doadores de Tecidos , Encéfalo/patologia , Encéfalo/diagnóstico por imagem , Brasil/epidemiologia , Imageamento por Ressonância Magnética , Estudos Retrospectivos , Resultado do Tratamento , Mucopolissacaridose I/genética , Mucopolissacaridose I/mortalidade , Idade de Início , Adrenoleucodistrofia/genética , Adrenoleucodistrofia/mortalidade , Condicionamento Pré-Transplante/métodos , Substância Branca/diagnóstico por imagem , Leucodistrofia Metacromática/genética , Leucodistrofia Metacromática/mortalidade
6.
JAMA Neurol ; 73(9): 1133-40, 2016 09 01.
Artigo em Inglês | MEDLINE | ID: mdl-27400410

RESUMO

IMPORTANCE: Allogeneic hematopoietic stem cell transplantation (HSCT) has been the only treatment option clinically available during the last 20 years for juvenile metachromatic leukodystrophy (MLD), reported with variable outcome and without comparison with the natural course of the disease. OBJECTIVE: To compare the long-term outcome of patients who underwent allogeneic HSCT with control patients who did not among a cohort with juvenile MLD. DESIGN, SETTING, AND PARTICIPANTS: Patients with juvenile MLD born between 1975 and 2009 and who received HSCT at a median age of 7 years (age range, 1.5-18.2 years) and nontransplanted patients with juvenile MLD born between 1967 and 2007 were included in this case-control study. The median follow-up after HSCT was 7.5 years (range, 3.0-19.7 years). Patients underwent HSCT at 3 German centers between 1991 and 2012. The analysis was done between July 2014 and August 2015. MAIN OUTCOMES AND MEASURES: Survival and transplantation-related mortality, loss of gross motor function (Gross Motor Function Classification in MLD), loss of any language function, and magnetic resonance imaging (MRI) severity score for cerebral changes. To explore prognostic factors at baseline, patients who underwent HSCT (hereafter, transplanted patients) were a priori divided into stable vs progressive disease, according to gross motor and cognitive function. RESULTS: Participants were 24 transplanted patients (11 boys, 13 girls) and 41 control patients (22 boys, 19 girls) who did not receive transplantation (hereafter, nontransplanted patients) with juvenile MLD. Among the transplanted patients, 4 children died of transplantation-related mortality, and 2 additional children died of rapid MLD progression 1.5 and 8.6 years after HSCT, resulting in a 5-year survival of 79% (19 of 24). Among the nontransplanted patients, 5-year survival after disease onset was 100% (41 of 41). However, 11 died of MLD progression, resulting in similar overall survival within the observation period. Nine of the long-term survivors after HSCT had disease progression, while 11 showed stable disease. Compared with the nontransplanted patients, the transplanted patients were less likely to lose their gross motor or language function and demonstrated significantly lower MRI severity scores at the latest examination. Patients after HSCT were more likely to have a stable disease course when undergoing HSCT at an early stage with no or only mild gross motor deficits (Gross Motor Function Classification in MLD level 0 or 1) and an IQ of at least 85, when age at disease onset was older than 4 years, or when MRI severity scores were low (preferably ≤17). CONCLUSIONS AND RELEVANCE: Among patients with juvenile MLD, patients who underwent HSCT had a better gross motor and language outcome and lower MRI severity scores compared with nontransplanted patients. Transplantation at a presymptomatic or early symptomatic stage of juvenile MLD is associated with a reasonable chance for disease stabilization.


Assuntos
Transplante de Células-Tronco Hematopoéticas/métodos , Leucodistrofia Metacromática/cirurgia , Resultado do Tratamento , Adolescente , Encéfalo/diagnóstico por imagem , Estudos de Casos e Controles , Criança , Pré-Escolar , Estudos de Coortes , Deficiências do Desenvolvimento/etiologia , Deficiências do Desenvolvimento/cirurgia , Feminino , Humanos , Lactente , Leucodistrofia Metacromática/complicações , Leucodistrofia Metacromática/diagnóstico por imagem , Leucodistrofia Metacromática/mortalidade , Imageamento por Ressonância Magnética , Masculino , Transplante Homólogo/métodos , Adulto Jovem
7.
Pediatr Neurol ; 49(3): 156-162.e1, 2013 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-23953952

RESUMO

BACKGROUND: Inherited leukodystrophies are progressive, debilitating neurological disorders with few treatment options and high mortality rates. Our objective was to determine national variation in the costs for leukodystrophy patients and to evaluate differences in their care. METHODS: We developed an algorithm to identify inherited leukodystrophy patients in deidentified data sets using a recursive tree model based on International Classification of Disease, 9th Edition, Clinical Modification, diagnosis and procedure charge codes. Validation of the algorithm was performed independently at two institutions, and with data from the Pediatric Health Information System (PHIS) of 43 US children's hospitals, for a 7-year period between 2004 and 2010. RESULTS: A recursive algorithm was developed and validated, based on six International Classification of Disease, 9th Edition, Clinical Modification, codes and one procedure code that had a sensitivity up to 90% (range 61-90%) and a specificity up to 99% (range 53-99%) for identifying inherited leukodystrophy patients. Inherited leukodystrophy patients comprise 0.4% of admissions to children's hospitals and 0.7% of costs. During 7 years, these patients required $411 million of hospital care, or $131,000/patient. Hospital costs for leukodystrophy patients varied at different institutions, ranging from two to 15 times more than the average pediatric patient. There was a statistically significant correlation between higher volume and increased cost efficiency. Increased mortality rates had an inverse relationship with increased patient volume that was not statistically significant. CONCLUSIONS: We developed and validated a code-based algorithm for identifying leukodystrophy patients in deidentified national datasets. Leukodystrophy patients account for $59 million of costs yearly at children's hospitals. Our data highlight potential to reduce unwarranted variability and improve patient care.


Assuntos
Efeitos Psicossociais da Doença , Hospitalização/economia , Hospitais Pediátricos , Leucodistrofia Metacromática , Algoritmos , Criança , Pré-Escolar , Estudos de Coortes , Feminino , Humanos , Leucodistrofia Metacromática/economia , Leucodistrofia Metacromática/epidemiologia , Leucodistrofia Metacromática/mortalidade , Masculino , Estudos Retrospectivos , Estados Unidos/epidemiologia
8.
Biol Blood Marrow Transplant ; 19(4): 616-24, 2013 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-23348427

RESUMO

Metachromatic leukodystrophy (MLD) is an inherited demyelinating disease that causes progressive neurologic deterioration, leading to severe motor disability, developmental regression, seizures, blindness, deafness, and death. The disease presents as a late-infantile, juvenile, or adult form. Hematopoietic stem cell transplantation has been shown to slow disease progression. The purpose of this longitudinal study was to evaluate long-term treatment outcomes after unrelated donor umbilical cord blood (UCB) transplantation in pediatric patients according to disease burden and age at onset (ie, late-infantile versus juvenile). Engraftment, survival, treatment-related toxicity, graft-versus-host disease, neurophysiologic measures, and neurodevelopmental function were assessed. To evaluate whether signal intensity abnormalities on magnetic resonance imaging (ie, modified Loes scores) predict post-transplant cognitive and gross motor development, a general linear mixed model was fit to the data. Twenty-seven patients underwent transplantation after myeloablative chemotherapy; 24 patients engrafted after the initial transplantation. Seven patients died of infection, regimen-related toxicity, or disease progression. Twenty patients (6 with late-infantile onset and 14 with juvenile onset) were followed for a median of 5.1 years (range, 2.4 to 14.7). We found that patients with motor function symptoms at the time of transplant did not improve after transplantation. Brainstem auditory evoked responses, visual evoked potentials, electroencephalogram, and/or peripheral nerve conduction velocities stabilized or improved in juvenile patients but continued to worsen in most patients with the late-infantile presentation. Pretransplant modified Loes scores were highly correlated with developmental outcomes and predictive of cognitive and motor function. Children who were asymptomatic at the time of transplantation benefited most from the procedure. Children with juvenile onset and minimal symptoms showed stabilization or deterioration of motor skills but maintained cognitive skills. Overall, children with juvenile onset had better outcomes than those with late-infantile onset. As in other leukodystrophies, early intervention correlated with optimal outcomes. We conclude that UCB transplantation benefits children with presymptomatic late-infantile MLD or minimally symptomatic juvenile MLD.


Assuntos
Transplante de Células-Tronco de Sangue do Cordão Umbilical , Doença Enxerto-Hospedeiro/terapia , Leucodistrofia Metacromática/terapia , Agonistas Mieloablativos/uso terapêutico , Adolescente , Idade de Início , Criança , Pré-Escolar , Progressão da Doença , Eletroencefalografia , Feminino , Doença Enxerto-Hospedeiro/diagnóstico , Doença Enxerto-Hospedeiro/mortalidade , Doença Enxerto-Hospedeiro/fisiopatologia , Humanos , Lactente , Leucodistrofia Metacromática/diagnóstico , Leucodistrofia Metacromática/mortalidade , Leucodistrofia Metacromática/fisiopatologia , Estudos Longitudinais , Imageamento por Ressonância Magnética , Masculino , Destreza Motora/efeitos dos fármacos , Condução Nervosa/efeitos dos fármacos , Análise de Sobrevida , Resultado do Tratamento , Doadores não Relacionados
9.
Dev Med Child Neurol ; 53(9): 850-855, 2011 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-21707604

RESUMO

AIM: Motor deterioration is a key feature in metachromatic leukodystrophy (MLD). The lack of data about its natural course impedes evaluation of therapeutic interventions. This study aimed to provide data about motor decline in MLD. METHOD: Fifty-nine patients (27 males, 32 females) with MLD (21 with late-infantile MLD and 38 with juvenile MLD) were recruited within a nationwide survey (the German LEUKONET). Median (range) age at onset was 17 months (9-27) for the group with late-infantile MLD and 6 years 2 months (2y 11mo-14y) for the group with juvenile MLD. Gross motor function was assessed using the Gross Motor Function Classification for MLD. RESULTS: In late-infantile MLD, all patients showed loss of all gross motor function until 3 years 4 months of age. Patients with juvenile MLD showed a more variable and significantly longer motor decline (p<0.001). For a patient with the juvenile form showing first gait disturbances, the probability of remaining stable for more than 1 year was 84%, and 51% for more than 2 years. Having lost independent walking, subsequent motor decline was as steep as in the late-infantile form (median 5 mo, interquartile range 3-22). INTERPRETATION: The course of motor disease was more variable in juvenile MLD with respect to onset and dynamics. However, the motor decline after the loss of independent walking was similarly steep in both forms. These data can serve as a reference for clinical studies that are topics of current research and allow definition of inclusion/exclusion criteria.


Assuntos
Leucodistrofia Metacromática/complicações , Transtornos dos Movimentos/etiologia , Adolescente , Idade de Início , Arilsulfatases/deficiência , Criança , Pré-Escolar , Terapia de Reposição de Enzimas/métodos , Feminino , Inquéritos Epidemiológicos , Humanos , Estimativa de Kaplan-Meier , Leucodistrofia Metacromática/tratamento farmacológico , Leucodistrofia Metacromática/epidemiologia , Leucodistrofia Metacromática/mortalidade , Masculino , Transtornos dos Movimentos/epidemiologia , Transtornos dos Movimentos/mortalidade , Estudos Retrospectivos , Estatísticas não Paramétricas
10.
Neurology ; 75(8): 718-25, 2010 Aug 24.
Artigo em Inglês | MEDLINE | ID: mdl-20660364

RESUMO

OBJECTIVES: Leukodystrophies are diseases of the white matter for which data concerning clinical characteristics, incidence, disease burden, and description of outcomes are sparse. The purpose of our study was to determine the incidence and most common types of inherited leukodystrophies in a population, the mortality and time course of deaths, common neurologic features in patients, and health care costs associated with leukodystrophies. METHODS: We conducted a retrospective, hospital- and clinic-based surveillance of inherited leukodystrophies among children younger than 18 years presenting to a regional children's hospital. We enrolled children evaluated from January 1, 1999, through December 31, 2007; clinical information was obtained from medical records. We calculated incidence based on state birth rates. RESULTS: A total of 122 children with an inherited leukodystrophy were identified; 542 patients were excluded. A total of 49% had epilepsy, 43% required a gastrostomy tube, and 32% had a history of developmental regression. Mortality was 34%; average age at death was 8.2 years. No final diagnosis was reported in 51% of patients. The most common diagnoses were metachromatic leukodystrophy (8.2%), Pelizaeus-Merzbacher disease (7.4%), mitochondrial diseases (4.9%), and adrenoleukodystrophy (4.1%). Endocrine abnormalities and hypoplastic cerebellum were noted in significant portions of patients (15% and 14%). Average yearly per-patient medical costs were $22,579. Population incidence was 1 in 7,663 live births. CONCLUSIONS: Inherited leukodystrophies are associated with substantial morbidity and mortality in children. Overall population incidence is higher than generally appreciated (1 in 7,663 live births). Most leukodystrophies remain undiagnosed, but a logical algorithm based on prevalence could aid testing.


Assuntos
Efeitos Psicossociais da Doença , Doenças Desmielinizantes Hereditárias do Sistema Nervoso Central/diagnóstico , Doenças Desmielinizantes Hereditárias do Sistema Nervoso Central/mortalidade , Adrenoleucodistrofia/diagnóstico , Adrenoleucodistrofia/economia , Adrenoleucodistrofia/mortalidade , Criança , Pré-Escolar , Diagnóstico Diferencial , Feminino , Doenças Desmielinizantes Hereditárias do Sistema Nervoso Central/economia , Humanos , Incidência , Leucodistrofia Metacromática/diagnóstico , Leucodistrofia Metacromática/economia , Leucodistrofia Metacromática/mortalidade , Masculino , Doença de Pelizaeus-Merzbacher/diagnóstico , Doença de Pelizaeus-Merzbacher/economia , Doença de Pelizaeus-Merzbacher/mortalidade , Estudos Retrospectivos
11.
J Child Neurol ; 25(5): 572-80, 2010 May.
Artigo em Inglês | MEDLINE | ID: mdl-20038527

RESUMO

Metachromatic leukodystrophy is a rare disorder with great clinical variability. We report the first case of triplets with the late infantile form of the disease and their systematic progression of symptoms. We reviewed the literature and identified all human studies that reported new cases since 1921. We analyzed survival by decade to assess the impact of historical changes in the management of care. Mean age at death and the 5-year survival from onset of symptoms for late infantile, juvenile, and adult phenotypes were 4.2 years and 24.9%, 17.4 years and 70.3%, and 43.1 years and 88.6%, respectively. The 5-year survival of cases reported after 1990 was significantly better than cases reported before 1970 in all subtypes of metachromatic leukodystrophy (late infantile: 52% vs 14%, juvenile: 100% vs 46%, adult: 95% vs 67%). Survival in the late infantile subtype was worse than that in other subtypes. Survival significantly improved over time in all subtypes.


Assuntos
Leucodistrofia Metacromática , Adulto , Idade de Início , Encéfalo/patologia , Progressão da Doença , Humanos , Lactente , Leucodistrofia Metacromática/genética , Leucodistrofia Metacromática/mortalidade , Leucodistrofia Metacromática/patologia , Fatores Sexuais , Trigêmeos
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...